(Q33367963)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107496%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

title

Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107496%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

main subject

metastatic breast cancer

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107496%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

G Gasparini

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107496%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

R Sarmiento

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107496%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

S Amici

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107496%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

R Longo

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107496%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

D Gattuso

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107496%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

M Zancan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107496%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

17 August 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107496%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107496%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107496%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107496%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

1867-1873

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16107496%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

cites work

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI393

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI393

The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI393

Epidermal growth factor-related peptides and their receptors in human malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI393

Transcriptional regulation by extracellular signals: mechanisms and specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI393

Clinical significance of the expression of epidermal growth factor and its receptor in esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI393

Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI393

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI393

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI393

Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI393

Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI393

Epidermal growth factor receptor expression and measurement in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI393

HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI393

A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI393

Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI393